These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 28210881)
21. Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies. Yakirevich E; Madison R; Fridman E; Mangray S; Carneiro BA; Lu S; Cooke M; Bratslavsky G; Webster J; Ross JS; Ali SM Eur Urol Oncol; 2021 Apr; 4(2):282-288. PubMed ID: 31412008 [TBL] [Abstract][Full Text] [Related]
22. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways. Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318 [TBL] [Abstract][Full Text] [Related]
23. Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. Suh JH; Schrock AB; Johnson A; Lipson D; Gay LM; Ramkissoon S; Vergilio JA; Elvin JA; Shakir A; Ruehlman P; Reckamp KL; Ou SI; Ross JS; Stephens PJ; Miller VA; Ali SM Oncologist; 2018 Jul; 23(7):776-781. PubMed ID: 29540602 [TBL] [Abstract][Full Text] [Related]
24. Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing. Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S Breast Cancer Res Treat; 2015 Jul; 152(2):305-12. PubMed ID: 26093648 [TBL] [Abstract][Full Text] [Related]
25. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast. Yoshida M; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Hiraoka N; Sekine S Br J Cancer; 2015 Oct; 113(8):1244-8. PubMed ID: 26355235 [TBL] [Abstract][Full Text] [Related]
26. A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions. Sim Y; Ng GXP; Ng CCY; Rajasegaran V; Wong SF; Liu W; Guan P; Nagarajan S; Ng WY; Thike AA; Lim JCT; Nasir NDBM; Tan VKM; Madhukumar P; Yong WS; Wong CY; Tan BKT; Ong KW; Teh BT; Tan PH BMC Med Genomics; 2019 Oct; 12(1):142. PubMed ID: 31647027 [TBL] [Abstract][Full Text] [Related]
27. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905 [TBL] [Abstract][Full Text] [Related]
28. Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors. Patel RR; Ramkissoon SH; Ross J; Weintraub L Pediatr Blood Cancer; 2020 Jul; 67(7):e28338. PubMed ID: 32386112 [TBL] [Abstract][Full Text] [Related]
29. Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer. Chen SH; Tse KP; Lu YJ; Chen SJ; Tian YF; Tan KT; Li CF Cancer Med; 2024 Jun; 13(12):e7384. PubMed ID: 38895905 [TBL] [Abstract][Full Text] [Related]
30. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075 [TBL] [Abstract][Full Text] [Related]
31. Genomic landscapes of breast fibroepithelial tumors. Tan J; Ong CK; Lim WK; Ng CC; Thike AA; Ng LM; Rajasegaran V; Myint SS; Nagarajan S; Thangaraju S; Dey S; Nasir ND; Wijaya GC; Lim JQ; Huang D; Li Z; Wong BH; Chan JY; McPherson JR; Cutcutache I; Poore G; Tay ST; Tan WJ; Putti TC; Ahmad BS; Iau P; Chan CW; Tang AP; Yong WS; Madhukumar P; Ho GH; Tan VK; Wong CY; Hartman M; Ong KW; Tan BK; Rozen SG; Tan P; Tan PH; Teh BT Nat Genet; 2015 Nov; 47(11):1341-5. PubMed ID: 26437033 [TBL] [Abstract][Full Text] [Related]
32. Malignant phyllodes tumour with lymph node metastasis: a diagnostic conundrum resolved by next generation DNA sequencing. Schwartz CJ; Krings G; Chen YY Histopathology; 2024 Jan; 84(2):409-411. PubMed ID: 37706238 [TBL] [Abstract][Full Text] [Related]
33. Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. Jacob JM; Ferry EK; Gay LM; Elvin JA; Vergilio JA; Ramkissoon S; Severson E; Necchi A; Killian JK; Ali SM; Schrock AB; Liu NW; Chung J; Miller VA; Stephens PJ; Welsh A; Corona RJ; Ross JS; Bratslavsky G J Urol; 2019 Mar; 201(3):541-548. PubMed ID: 30291913 [TBL] [Abstract][Full Text] [Related]
34. Comparative genomic analysis of primary tumors and metastases in breast cancer. Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851 [TBL] [Abstract][Full Text] [Related]
35. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast. Piscuoglio S; Murray M; Fusco N; Marchiò C; Loo FL; Martelotto LG; Schultheis AM; Akram M; Weigelt B; Brogi E; Reis-Filho JS Histopathology; 2015 Nov; 67(5):719-29. PubMed ID: 25855048 [TBL] [Abstract][Full Text] [Related]
36. Genomic characteristics of two breast malignant phyllodes tumors during pregnancy and lactation identified through whole-exome sequencing. Lei T; Shen M; Deng X; Shi Y; Peng Y; Wang H; Chen T Orphanet J Rare Dis; 2022 Oct; 17(1):382. PubMed ID: 36271373 [TBL] [Abstract][Full Text] [Related]
37. Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. Jardim DL; Conley A; Subbiah V Orphanet J Rare Dis; 2013 Jul; 8():112. PubMed ID: 23895135 [TBL] [Abstract][Full Text] [Related]
38. Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Liang WS; Vergilio JA; Salhia B; Huang HJ; Oki Y; Garrido-Laguna I; Park H; Westin JR; Meric-Bernstam F; Fabrizio D; Miller VA; Stephens PJ; Fanale MA; Ross JS; Janku F Oncologist; 2019 Feb; 24(2):219-228. PubMed ID: 30108156 [TBL] [Abstract][Full Text] [Related]
39. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409 [TBL] [Abstract][Full Text] [Related]
40. MED12 exon 2 and TERT promoter mutations in primary and recurrent breast fibroepithelial lesions. Hu Y; Li G; Wang L; Zhang L; Guan J; Wang J Pathol Int; 2021 Dec; 71(12):814-822. PubMed ID: 34597441 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]